This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosen, L. Search for Related Content PubMed PubMed Citation Articles by Rosen, L.

Antiangiogenic Strategies and Agents in Clinical Trials

University of California Los Angeles School of Medicine, Los Angeles, California, USA

Correspondence: Lee Rosen, M.D., University of California Los Angeles, 10945 Le Conte Avenue, PVU Bldg., Suite 2333, Los Angeles, CA 90095, USA. Telephone: 310-206-3170; Fax: 310-206-5414; e-mail: LSROSEN{at}mednet.ucla.edu

The understanding that the growth of tumors depends on the acquisition of a blood supply has led to the development of new therapies for cancer and other angiogenic diseases based on inhibition of neovascularization. This review examines the role of angiogenesis in cancer progression and describes various strategies for interfering with this process. The developmental status of angiogenesis inhibitors in human clinical trials is presented, including their proposed mechanisms of action. Standard chemotherapeutic agents and angiogenesis inhibitors are compared, noting that different end points might need to be considered in clinical trials and that drug resistance may be less of a problem with antiangiogenic therapy than with conventional chemotherapy regimens. The suggestion is made that cytotoxic chemotherapy and angiogenesis inhibitors used in combination may produce complementary therapeutic benefits in the treatment of cancer.

Key Words. Angiogenesis • Angiogenesis inhibitors • Cytotoxic chemotherapy • Vascular endothelial growth factor

This article has been cited by other articles:

				M.-E. Jockovich, T. G. Murray, E. Escalona-Benz, E. Hernandez, and W. Feuer Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1264 - 1268. [Abstract] [Full Text] [PDF]

				J. C. Miller, H. H. Pien, D. Sahani, A. G. Sorensen, and J. H. Thrall Imaging Angiogenesis: Applications and Potential for Drug Development J Natl Cancer Inst, February 2, 2005; 97(3): 172 - 187. [Abstract] [Full Text] [PDF]

				E. Escalona-Benz, M.-E. Jockovich, T. G. Murray, B. Hayden, E. Hernandez, W. Feuer, and J. J. Windle Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 8 - 11. [Abstract] [Full Text] [PDF]

				M Kothari, A Guermazi, D White, J Suhy, and C Reinhold Imaging in antiangiogenesis trial: a clinical trials radiology perspective Br. J. Radiol., December 1, 2003; 76(suppl_1): S92 - S96. [Abstract] [Full Text] [PDF]

				Y. Chao, C.-P. Li, G.-Y. Chau, C.-P. Chen, K.-L. King, W.-Y. Lui, S.-H. Yen, F.-Y. Chang, W.-K. Chan, and S.-D. Lee Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery Ann. Surg. Oncol., May 1, 2003; 10(4): 355 - 362. [Abstract] [Full Text] [PDF]

				L. M. Cross, M. A. Cook, S. Lin, J.-N. Chen, and A. L. Rubinstein Rapid Analysis of Angiogenesis Drugs in a Live Fluorescent Zebrafish Assay Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 911 - 912. [Full Text] [PDF]

				S. L. Franklin, R. J. Ferry Jr., and P. Cohen Rapid Insulin-Like Growth Factor (IGF)-Independent Effects of IGF Binding Protein-3 on Endothelial Cell Survival J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 900 - 907. [Abstract] [Full Text] [PDF]

				J. P. Eder Jr, J. G. Supko, J. W. Clark, T. A. Puchalski, R. Garcia-Carbonero, D. P. Ryan, L. N. Shulman, J. Proper, M. Kirvan, B. Rattner, et al. Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily J. Clin. Oncol., September 15, 2002; 20(18): 3772 - 3784. [Abstract] [Full Text] [PDF]

				R. J. Griffin, B. W. Williams, R. Wild, J. M. Cherrington, H. Park, and C. W. Song Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response Cancer Res., March 1, 2002; 62(6): 1702 - 1706. [Abstract] [Full Text] [PDF]

				J. Griggs, J. N. Skepper, G. A. Smith, K. M. Brindle, J. C. Metcalfe, and R. Hesketh Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4 Am. J. Pathol., March 1, 2002; 160(3): 1097 - 1103. [Abstract] [Full Text] [PDF]

				S. Lamy, D. Gingras, and R. Beliveau Green Tea Catechins Inhibit Vascular Endothelial Growth Factor Receptor Phosphorylation Cancer Res., January 1, 2002; 62(2): 381 - 385. [Abstract] [Full Text] [PDF]

				R. S. Kerbel Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results J. Clin. Oncol., September 15, 2001; 19(90001): 45s - 51. [Full Text] [PDF]

				F. Nilsson, H. Kosmehl, L. Zardi, and D. Neri Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice Cancer Res., January 1, 2001; 61(2): 711 - 716. [Abstract] [Full Text]